ELVN Common Stock · Transaction Jun 17, 2024 · Filed Jul 22, 2024 · Amount pending receipt enrichment
XNAS · ELVN
+0.32% · +$0.1900 · Vol 696.1K
Market closed · last close 4:00 PM ET · price as of 16:00:49 ET
Enliven Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
$60.46
Veridion Score
BETAHIGH CONF · 6/6 factorsFri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET · ELVN
MethodologyELVN
Enliven Therapeutics, Inc. Common Stock
Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
STRONG
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
80/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ELVN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Enliven Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONSListed since
2023
Employees
67
Country
US
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$60.18
Day high
$61.77
Day low
$59.73
Previous close
$60.27
52W high
$61.77
-2.11% from high
52W low
$15.14
97% of range
Market cap
$4.4B
EPS
$-1.7600
Beta
0.38
Shares out
73.3M
Volume
696.1K
0.55× rel vol
Avg volume
1.3M
VWAP
$60.44
Price history computed in-house
1W
+4.17%
1M
+18.34%
3M
+42.93%
1Y
+241.78%
YTD
+292.60%
SMA 50 $48.33 · above
SMA 200 $33.76 · above
52W position 97%
ELVN overview
Veridion Score
80
6 of 6 factors measured
Congress receipts
2
Michael T. McCaul · Sale
13F holders
None on file
Related filings and maps
Public disclosures
Congress activity in ELVN
Official filing ↗
ELVN Common Stock · Transaction Jul 21, 2023 · Filed Aug 16, 2023 · Amount pending receipt enrichment
Federal contracts
ELVN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ELVN in this window.
Lobbying spend
ELVN lobbying filings, year to date.
Registered lobbying filings matched to Enliven Therapeutics, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ELVN in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ELVN.
Options
Sovereign unlock shows live options positioning for ELVN.